FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3sBqfi3
via IFTTT